![Arsenic Trioxide Consolidation Allows Anthracycline Dose Reduction for Pediatric Patients With Acute Promyelocytic Leukemia: Report From the Children's Oncology Group Phase III Historically Controlled Trial AAML0631 | Journal of Clinical Oncology Arsenic Trioxide Consolidation Allows Anthracycline Dose Reduction for Pediatric Patients With Acute Promyelocytic Leukemia: Report From the Children's Oncology Group Phase III Historically Controlled Trial AAML0631 | Journal of Clinical Oncology](https://ascopubs.org/na101/home/literatum/publisher/asco/journals/content/jco/2017/jco.2017.35.issue-26/jco.2016.71.6183/20171002/images/large/jco.2016.71.6183t1.jpeg)
Arsenic Trioxide Consolidation Allows Anthracycline Dose Reduction for Pediatric Patients With Acute Promyelocytic Leukemia: Report From the Children's Oncology Group Phase III Historically Controlled Trial AAML0631 | Journal of Clinical Oncology
![Management of relapsed and refractory childhood acute promyelocytic leukaemia: recommendations from an international expert panel - Abla - 2016 - British Journal of Haematology - Wiley Online Library Management of relapsed and refractory childhood acute promyelocytic leukaemia: recommendations from an international expert panel - Abla - 2016 - British Journal of Haematology - Wiley Online Library](https://onlinelibrary.wiley.com/cms/asset/2de653bc-d4e5-4829-8650-d75c3b6a88be/bjh14313-fig-0001-m.jpg)
Management of relapsed and refractory childhood acute promyelocytic leukaemia: recommendations from an international expert panel - Abla - 2016 - British Journal of Haematology - Wiley Online Library
![Acute Promyelocytic Leukemia: A History over 60 Years—From the Most Malignant to the most Curable Form of Acute Leukemia | SpringerLink Acute Promyelocytic Leukemia: A History over 60 Years—From the Most Malignant to the most Curable Form of Acute Leukemia | SpringerLink](https://media.springernature.com/lw685/springer-static/image/art%3A10.1007%2Fs40487-018-0091-5/MediaObjects/40487_2018_91_Fig1_HTML.png)
Acute Promyelocytic Leukemia: A History over 60 Years—From the Most Malignant to the most Curable Form of Acute Leukemia | SpringerLink
![Retinoic acid and arsenic trioxide induce lasting differentiation and demethylation of target genes in APL cells | Scientific Reports Retinoic acid and arsenic trioxide induce lasting differentiation and demethylation of target genes in APL cells | Scientific Reports](https://media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fs41598-019-45982-7/MediaObjects/41598_2019_45982_Fig1_HTML.png)
Retinoic acid and arsenic trioxide induce lasting differentiation and demethylation of target genes in APL cells | Scientific Reports
![Pharmacokinetic-pharmacodynamic effects of apomorphine sublingual film (APL-130277) for the rapid management of OFF episodes in patients with Parkinson's disease - MDS Abstracts Pharmacokinetic-pharmacodynamic effects of apomorphine sublingual film (APL-130277) for the rapid management of OFF episodes in patients with Parkinson's disease - MDS Abstracts](https://www.mdsabstracts.org/wp-content/uploads/2016/04/552405_figure_1_with_title.jpg)
Pharmacokinetic-pharmacodynamic effects of apomorphine sublingual film (APL-130277) for the rapid management of OFF episodes in patients with Parkinson's disease - MDS Abstracts
![Risk-adapted treatment of acute promyelocytic leukemia: results from the International Consortium for Childhood APL - ScienceDirect Risk-adapted treatment of acute promyelocytic leukemia: results from the International Consortium for Childhood APL - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S0006497120320425-fx1.jpg)
Risk-adapted treatment of acute promyelocytic leukemia: results from the International Consortium for Childhood APL - ScienceDirect
![Blockade of deubiquitinase YOD1 degrades oncogenic PML/RARα and eradicates acute promyelocytic leukemia cells - ScienceDirect Blockade of deubiquitinase YOD1 degrades oncogenic PML/RARα and eradicates acute promyelocytic leukemia cells - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S2211383521004123-ga1.jpg)
Blockade of deubiquitinase YOD1 degrades oncogenic PML/RARα and eradicates acute promyelocytic leukemia cells - ScienceDirect
![Safety of sublingual apomorphine film (APL-130277) for the treatment of OFF episodes in patients with Parkinson's disease: Preliminary Results from a Phase III Study - MDS Abstracts Safety of sublingual apomorphine film (APL-130277) for the treatment of OFF episodes in patients with Parkinson's disease: Preliminary Results from a Phase III Study - MDS Abstracts](https://www.mdsabstracts.org/wp-content/uploads/2017/05/0037-001034_001.jpg)
Safety of sublingual apomorphine film (APL-130277) for the treatment of OFF episodes in patients with Parkinson's disease: Preliminary Results from a Phase III Study - MDS Abstracts
![Anaesthetic management of a patient undergoing unilateral phacoemulsification with concurrent diabetes mellitus | The Veterinary Nurse Anaesthetic management of a patient undergoing unilateral phacoemulsification with concurrent diabetes mellitus | The Veterinary Nurse](https://www.theveterinarynurse.com/media/74168/assets-vetn2019105270_t01.jpg?&width=780&quality=60)
Anaesthetic management of a patient undergoing unilateral phacoemulsification with concurrent diabetes mellitus | The Veterinary Nurse
The CCL2/CCR2 Axis Affects Transmigration and Proliferation but Not Resistance to Chemotherapy of Acute Myeloid Leukemia Cells | PLOS ONE
![IJMS | Free Full-Text | Acute Promyelocytic Leukemia in Children: A Model of Precision Medicine and Chemotherapy-Free Therapy | HTML IJMS | Free Full-Text | Acute Promyelocytic Leukemia in Children: A Model of Precision Medicine and Chemotherapy-Free Therapy | HTML](https://www.mdpi.com/ijms/ijms-22-00642/article_deploy/html/images/ijms-22-00642-g001.png)